FDA approves valbenazine to treat tardive dyskinesia in adults

FDA approves valbenazine to treat tardive dyskinesia in adults

The AP (4/11, Johnson) reports that the Food and Drug Administration has approved Neurocrine Biosciences’ Ingrezza (valbenazine) for the treatment of tardive dyskinesia in adults. The company “didn’t disclose the drug’s list price, but said it will when it begins offering the once-a-day capsule for sale in May.” Another drug intended to treat tardive dyskinesia made by Teva Pharmaceuticals “is expected to win FDA approval in late August.”